Search: onr:"swepub:oai:DiVA.org:uu-97241" >
Ghrelin Immunoreact...
Ghrelin Immunoreactive Cells in Gastric Endocrine Tumors and Their Relation to Plasma Ghrelin Concentration : Ghrelin in Gastric Endocrine Tumors
-
- Tsolakis, Apostolos V. (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi
-
- Stridsberg, Mats (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Klinisk kemi
-
- Grimelius, Lars (author)
- Uppsala universitet,Institutionen för genetik och patologi
-
show more...
-
- Portela-Gomes, Guida M. (author)
- Uppsala universitet,Institutionen för genetik och patologi
-
Falkmer, Sture E. (author)
-
Waldum, Helge L. (author)
-
- Janson, Eva Tiensuu (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi
-
show less...
-
(creator_code:org_t)
- 2008
- 2008
- English.
-
In: Journal of Clinical Gastroenterology. - 0192-0790 .- 1539-2031. ; 42:4, s. 381-388
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- GOALS: Our aim was to elucidate the incidence and distribution pattern of ghrelin-immunoreactive (IR) cells in various types of human gastric endocrine tumors, and their surrounding mucosa, and relate the findings to total ghrelin concentrations in plasma. BACKGROUND: It has been demonstrated previously, that ghrelin-IR cells are present not only in normal human gastric oxyntic mucosa, but also in all types of enterochromaffinlike (ECL) cell carcinoids (ECL-CCs), and in mucosal regions affected by ECL cell hyperplasia. STUDY: Forty-eight gastric endocrine tumors were included in the study: 32 type I ECL-CCs, 3 type II, 9 type III, 1 non-ECL-CC, and 3 poorly differentiated endocrine carcinomas. The tumors were analyzed immunohistochemically with antibodies raised versus chromogranin A, synaptophysin, serotonin, somatostatin, vesicular monoamine transporter 2 and ghrelin. Total ghrelin in plasma was measured in 20 patients, using a commercial radioimmunoassay kit. RESULTS: Ghrelin-IR cells were found in all types I and II ECL-CCs but in only a few cases of the other tumors. Ghrelin-IR cells were also found among the hyperplastic endocrine cells in the mucosa surrounding types I and II, where they showed diffuse, linear, nodular and adenomatoid hyperplasia patterns. In type III ECL-CCs and poorly differentiated endocrine carcinomas, only diffuse and linear ghrelin-IR cell hyperplasia was present in the oxyntic mucosa in about half of the cases, whereas the mucosa of the non-ECL-CC did not show this feature. CONCLUSIONS: Despite the frequent occurrence of ghrelin-IR cells in both the neoplastic parenchyma and the oxyntic mucosa, plasma total ghrelin concentrations remained within the reference range and can therefore not be used as a clinical marker to identify ghrelin expressing ECL-CCs or ghrelin cell hyperplasia.
Keyword
- ECL cells
- gastric endocrine tumor
- ghrelin
- immunohistochemistry
- radioimmunoassay
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database